Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib
Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target accelerated and full FDA approval, with pivotal data expected in H1 '27 as a major catalyst. Recent $93m capital raise extends cash runway into 2028, supporting regulatory milestones and mitigating near-term funding risk.
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC
Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) by 71.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 457,322 shares of the company's stock after selling 1,141,944 shares during the quarter. Almitas Capital
Zentalis Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Madelyn D. Purcell Pfizer Inc | 953,834 | $2.89M | $4.09M | $1.2M | 41.58% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 61,412 | $297,850 | $259,158.64 | -$38,691.36 | -12.99% |
| BG Bart Gancher Intech Investment Management LLC | 10,460 | $50,731 | $43,409 | -$7,322 | -14.43% |
 Joseph Castro Nuveen LLC | 66,674 | $323,369 | $276,697.1 | -$46,671.9 | -14.43% |
 Lindsey Seagraves Carson Advisory Inc. | 21,170 | $85,994.2 | $87,855.5 | $1,861.3 | 2.16% |
Zentalis Pharmaceuticals, Inc. (ZNTL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zentalis Pharmaceuticals, Inc. ever had a stock split?
Zentalis Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Julia Marie Eastland CEO | NASDAQ (NMS) Exchange | 98943L107 CUSIP |
| US Country | 106 Employees | - Last Dividend | - Last Split | 3 Apr 2020 IPO Date |
Overview
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical entity committed to the discovery and development of innovative small molecule treatments aimed at various cancers. Established in 2014 and headquartered in New York, New York, the company dedicates its efforts to advancing oncology treatments through scientific excellence and strategic partnerships. Zentalis has fostered licensing agreements and collaborations with industry leaders such as Pfizer, Inc., Eli Lilly and Company, GlaxoSmithKline, along with other notable organizations like Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; and Zentera Therapeutics (Cayman), Ltd. These alliances underscore Zentalis' commitment to leveraging collective expertise and resources to push the boundaries of cancer treatment.
Products and Services
- ZN-c3
ZN-c3 stands as Zentalis' premier product candidate, underpinned by its role as a WEE1 inhibitor, a crucial protein tyrosine kinase in cancer cell proliferation. Currently, ZN-c3 is undergoing a Phase 2 clinical trial aimed at treating advanced solid tumors, showcasing its versatility with a dual approach; it is also in a Phase 1/2 trial as a singular therapy and part of a Phase 1b trial combined with chemotherapy, specifically targeting patients with platinum-resistant ovarian cancer. Additionally, a Phase 2 monotherapy trial is evaluating ZN-c3 as a tumor agnostic option, dependent on predictive biomarker identification.
- ZN-c5
As an oral selective estrogen receptor degrader, ZN-c5 presents a promising treatment for advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. It is currently in a Phase 1/2 clinical trial, aiming to offer a new therapeutic avenue for patients battling this form of cancer.
- ZN-d5
ZN-d5 encompasses a selective inhibitor of B-cell lymphoma 2, venturing into the realm of hematologic malignancies. It finds its clinical value in a Phase 1 trial focused on non-Hodgkin's lymphoma and acute myelogenous leukemia, potentially broadening the spectrum of available treatments for these conditions.
- ZN-e4
Targeting a different aspect of oncology, ZN-e4 is an irreversible inhibitor of mutant epidermal growth factor receptor. Its involvement in a Phase 1/2 clinical trial aims to treat advanced non-small cell lung cancer, offering hope for a novel therapeutic strategy against this challenging diagnosis.
- BCL-xL heterobifunctional degraders
Zentalis is innovating beyond its primary candidates by developing BCL-xL heterobifunctional degraders. These are based on E3 ligases not expressed in platelets, sidestepping the common adverse effect of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. This initiative represents the company's forward-thinking approach to overcoming treatment barriers in cancer therapy.
